AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Novartis' (NVS.US) new 1st-class radioactive cancer therapy has been approved for clinical trials in China.
Generated by AI AgentMarket Intel
Monday, Mar 3, 2025 8:40 am ET1min read
On March 3, the National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE) officially announced that
(NVS.US) had been approved to conduct clinical trials for its 1st-class new drug [225Ac]Ac-PSMA-617 injection, which is intended to treat metastatic hormone-resistant prostate cancer positive for PSMA after [177Lu]Lu-PSMA targeted therapy. According to Novartis' pipeline information on its website, this is a radioactive therapy targeting PSMA (development code: AAA817), which has entered the 2/3 phase clinical research stage in the international market. This is the first time the product has been approved for IND in China.
Market Intel
Global insights driving the market strategies of tomorrow.
Latest Articles
Occidental Petroleum Seeks $100B OxyChem Sale to Cut Debt
Sep.28 2025
Trump Demands Microsoft Fire Global Affairs President
Sep.27 2025
Dow Jones Rises 0.49% as Nasdaq Golden Dragon China Index Falls 2%
Sep.26 2025
Ralph Lauren Wins Eight-Year China Trademark Battle
Sep.26 2025
Perpetua Resources Seeks Partners for US Antimony Refinery
Sep.26 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet